Oncology

dltHub's recent Snowflake award isn't just a trophy. It signals a tectonic shift where AI automates the complex plumbing of the digital economy.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

The struggling biopharma secures cash, but its creative financing deal could dilute existing shareholder value by over 30%. A deep dive into the high-stakes world of biotech funding.

With a potential $4 billion on the line, CytomX and Regeneron are building a new class of cancer therapies designed to act like autonomous agents in the body.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

By turning 2,792 miles of GPS data into a stop-motion film, a nonprofit is redefining advocacy and inviting the world to run for a cause.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

As Nanobiotix joins Europe's tech elite, its nanotech cancer therapy gains a powerful spotlight, signaling a new era for physics-based medicine.

Early data shows a first-in-class oral drug helps immunotherapy work again in resistant tumors, offering a glimpse of hope where options are running out.

With over 7 million Americans facing Alzheimer's, an innovative online study empowers you to monitor your brain health and join the fight from home.